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Abstract
Background: Several studies suggest beneficial effects of perioperative statin therapy on postoperative outcome
after cardiac surgery. However, recent randomized controlled trials (RCTs) show potential detrimental effects. The
objective of this systematic review is to examine the association between perioperative statin therapy and clinical
outcomes in cardiac surgery patients.
Methods: Electronic databases were searched up to 1 November 2016 for RCTs of preoperative statin therapy versus
placebo or no treatment in adult cardiac surgery. Postoperative outcomes were acute kidney injury, atrial fibrillation,
myocardial infarction, stroke, infections, and mortality. We calculated odds ratios (ORs) and 95% confidence intervals
(CIs) using fixed-effects meta-analyses. Primary analysis was restricted to trials with low risk of bias according to
Cochrane methodology, and sensitivity analyses examined whether the risk of bias of included studies was associated
with different results. We performed trial sequential analysis (TSA) to test the strength of the results.
Results: We included data from 23 RCTs involving 5102 patients. Meta-analysis of trials with low risk of bias showed
that statin therapy was associated with an increase in acute kidney injury (314 of 1318 (23.82%) with statins versus 262
of 1319 (19.86%) with placebo; OR 1.26 (95%CI 1.05 to 1.52); p = 0.01); these results were supported by TSA. No
difference in postoperative atrial fibrillation, myocardial infarction, stroke, infections, or mortality was present. On
sensitivity analysis, statin therapy was associated with a slight increase in hospital mortality. Meta-analysis including
also trials with high or unclear risk of bias showed no beneficial effects of statin therapy on any postoperative
outcomes.
Conclusions: There is no evidence that statin therapy in the days prior to cardiac surgery is beneficial for patients’
outcomes. Particularly, statins are not protective against postoperative atrial fibrillation, myocardial infarction, stroke,
or infections. Statins are associated with a possible increased risk of acute kidney injury and a detrimental effect on
hospital survival could not be excluded. Future RCTs should further evaluate the safety profile of this therapy in
relation to patients’ outcomes and assess the more appropriate time point for discontinuation of statins before
cardiac surgery.
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Background
Postoperative complications after cardiac surgery are asso-
ciated with higher morbidity and mortality, and increased
costs [1]. Non-fatal complications are relatively common
[2, 3], with the most important ones being acute kidney
injury (AKI) [4, 5], atrial fibrillation (AF) [6, 7], myocardial
infarction (MI), and stroke [8], while the overall 30-day
mortality is approximately 3%.
Current American guidelines [9] highly recommend
preoperative treatment with statins in all patients under-
going coronary artery bypass grafting (CABG), irrespective
of their preoperative lipid profile, with rapid restoration
of statin therapy after surgery. Discontinuation of statin
treatment is not recommended before or after CABG in
patients without side effects to therapy [9]. Therefore,
nowadays more than half of patients scheduled for CABG
receive perioperative statins [10] in compliance with
present guidelines.
Moreover, knowledge of pleiotropic anti-inflammatory
effects of statins [11, 12] has led to consider statins a
potential therapy able to modulate the inflammatory
response to cardiac surgery. In support of this assumption,
several randomized controlled trials (RCTs), reporting on
inflammatory markers and statin use in perioperative
cardiac surgery, have demonstrated reduction in inflam-
matory cytokines [12]. In several retrospective non-
randomized studies, preoperative statins have been as-
sociated with lower postoperative MI, mortality [13–17],
AF [17, 18], neurological dysfunction [16], renal dysfunc-
tion [19], and infection [20]. However, the largest recently
published RCTs show that perioperative statins do not
prevent postoperative AF or myocardial damage and could
be even associated with higher postoperative AKI [21, 22].
Due to the contrasting results and equivocal quality of
evidence in the current literature, we performed a system-
atic review and meta-analysis of RCTs to examine the ef-
fects of perioperative statin therapy on postoperative AKI,
AF, MI, stroke, infections, and mortality in adult cardiac
surgical patients.
Methods
We conducted a systematic review and meta-analysis of
randomized trials, in compliance to the Cochrane meth-
odology [23] and Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [24],
and according to a pre-published protocol on the
PROSPERO database (CRD42016039509 [25]). A complete
PRISMA 2009 checklist is provided in the supplementary
material (Additional file 1). This study had no funding and
authors did not have any conflicts of interest.
Search strategy
Two trained investigators (AP, AB) independently searched
PubMed, the Cochrane Central Register of clinical trials,
and EMBASE (last updated on 1 November 2016) for
appropriate articles. The full PubMed search strategy is
presented in the supplementary material (Additional file 1).
The search strategy was designed to include any RCT ever
performed with perioperative statin therapy compared to
control in adult humans in a cardiac surgery setting. No
language restriction was enforced. References for eligible
studies and identified reviews were searched by hand.
Study selection
Records obtained from searches were first independently
examined at an abstract level by two trained investigators
(AP and AB). Following the initial abstract assessment, all
identified studies were acquired as full-text. Eligible
studies met the following criteria defined as patient, popu-
lation or problem, intervention, comparison, outcomes and
study design (PICOS): (1) population: adult cardiac surgery
patients; (2) intervention: administration of perioperative
statin therapy; (3) comparison intervention: placebo or no
active intervention as control; (4) outcome: any primary or
secondary outcome of the present systematic review (see
subsequent text); and (5) study design: randomized con-
trolled trial. The exclusion criteria were pediatric studies
and overlapping populations. Two investigators (AP and
AB) independently assessed selected studies for the final
analysis, with eventual divergences finally resolved by con-
sensus with a third author (GL).
Data abstraction and study characteristics
Two authors (AP and AB) independently extracted data
from studies and entered them into a predefined database.
Discrepancies were identified and resolved through discus-
sion with a third author (GL) if necessary. We collected
potential sources of significant clinical heterogeneity such
as study design, clinical setting, details of the case and con-
trol interventions, data on the predefined outcomes, and
information necessary to assess risk of bias.
The primary outcomes were postoperative AKI, postop-
erative AF, postoperative MI, postoperative stroke, and
postoperative infection. The secondary outcome was
mortality at the longest available follow up. The outcomes
were reported in the present review as per-author defin-
ition. If the data on the postoperative outcomes were ab-
sent or incomplete, missing data were requested from the
corresponding authors of the study. The data extraction
followed the intention-to-treat basis whenever possible.
Assessment of quality of the included studies
We used the Cochrane approach [23, 26] to evaluate the
methodological quality of each included trial (Additional
file 1). Each trial was finally judged to be of low, unclear,
or high risk of bias. The quality of the evidence for
each outcome was summarized with the grading of
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recommendations assessment, development, and evalu-
ation (GRADE) method [23, 26, 27].
Statistical analysis
For each outcome, we calculated the odds ratio (OR)
with 95% confidence intervals (CI). We reported the pro-
portion of patients with the outcome in each group and
the p value for the comparison between the groups. A
p value <0.05 was considered significant. In the case of
statistically significant ORs, we calculated the number
needed to treat (NNT) or number needed to harm
(NNH). The primary analysis of the present review was
restricted to studies with low risk of bias, as suggested
by the Cochrane Collaboration tool for assessing risk
of bias [26].
Heterogeneity was explored by the Cochran Q statistic
and characterized with I2. We used a fixed-effect model
for meta-analysis in the absence of significant heterogen-
eity, defined as a p value >0.10 and I2 < 50%. In case of sig-
nificant heterogeneity, we employed the random-effects
model except if few trials dominated the available evi-
dence or if significant publication bias was present, as
random-effects meta-analysis in these contexts can give
inappropriately high weight to smaller studies [23]. Two
investigators (AP and AB) independently evaluated publi-
cation bias and small trials bias, analyzing a funnel plot
and assessing the asymmetry in the funnel plot of trial size
against treatment effect.
We performed sensitivity analyses for each outcome in
order to assess the influence of risk of bias in the trials,
including all eligible trials despite their risk of bias and
including only trials with unclear or high risk of bias. In
accordance with the Cochrane methodology [23], we per-
formed sensitivity analysis for each outcome to investigate
whether choice of summary statistic (OR, risk ratio (RR),
risk difference (RD)) is critical to the results of the meta-
analysis. We performed further sensitivity analysis for each
outcome including only trials enrolling more than 200
patients or including only placebo-controlled studies.
Two authors independently evaluated the possibility of
significant conflicts of interest within each study. They
evaluated the funding of the study, the potential for au-
thors’ conflicts of interests, the methodological quality of
the study, and the positive/negative/indifferent findings
of the study over statin. In case of possible or unclear in-
dustrial conflicts of interest among studies included in
the analysis, we performed sensitivity analysis excluding
them. The results of sensitivity analyses are reported
only if significantly different from the primary analysis.
Post-hoc meta-regression was employed to examine the
possible influence of length of preoperative therapy,
proportion of CABG patients, trial size, and publication
year on clinical outcomes in all eligible trials. Post-hoc
subgroup analyses were performed on trials that included
only statin-naïve patients, on trials enrolling mixed
populations (statin-naïve and chronic statin therapy),
and on trials that randomized patients on a postoperative
statin regimen or not. Subgroup differences were tested
using chi-square statistics [23]. The meta-analysis was
performed using Review Manager (RevMan (Computer
program), Version 5.3. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014).
Finally, to confirm the validity of our findings, we per-
formed post-hoc trial sequential analysis (TSA) [28–30],
with the intent of maintaining an overall 5% risk of type
I error and a 20% risk of type II error, at a power of
80%. Relative risk reduction (RRR) or relative risk increase
(RRI) for each outcome was derived from the literature
in order to evidence a clinically meaningful difference
(Additional file 1). We used the Copenhagen Trial Unit
TSA software (version 1.0, http://www.ctu.dk/tsa).
Results
Study characteristics
In total, 3699 references were examined. Major exclu-
sions are presented in the supplementary data together
with the reasons for exclusion (Additional file 1). Finally,
23 articles (5102 randomized patients) [21, 22, 31–51]
were included in the analysis (Fig. 1).
Characteristics of the 23 trials are listed in Table 1 and
Additional file 1. Eligible trials included from 30 to 1922
patients and were all single-center studies. In six cases
we received data from the authors on further outcomes
[21, 31, 38, 40, 42, 51].
All trials included elective cardiac surgery patients and
the most represented procedure was CABG, performed
in 78.01% of the patients.
Statins were administered preoperatively in all trials,
with the length of treatment ranging from 1 to 28 days
(median 7 days). The total duration of statin treatment
varied from 2 to 33 days; the variety of statin doses and
regimens are shown in Table 1. The randomized treat-
ment was also administered postoperatively in 8 trials
[22, 34, 35, 38, 42, 44, 45, 51]. Atorvastatin (20 to
80 mg) was administered in 14 trials, Simvastatin
20 mg in 3 trials, Rosuvastatin 20 mg in 2 trials, Fluvas-
tatin 80 mg in 1 trial, and Pravastatin 40 mg in 1 trial.
In one case the statin regimen was not specified [41].
Placebo was administered as control in 16 trials and in
7 trials there was no intervention administered as
control [31, 34, 37, 45, 49–51].
Ten trials reported postoperative data on AKI (3354
patients), 19 trials on AF (4737 patients), 19 trials on MI
(4283 patients), 12 trials on stroke (3631 patients), 7 trials
on infections (2961 patients), and 18 trials on mortality
(4157 patients).
Three trials were judged at low risk of bias in all
bias domains [21, 22, 44]. Five trials were scored as
Putzu et al. Critical Care  (2016) 20:395 Page 3 of 14
having unclear risk of bias [35, 36, 38, 42, 46] and 15
trials were at high risk of bias (Fig. 2 and Additional
file 1). The overall quality of evidence according to
GRADE was reported for each outcome (Table 2 and
Additional file 1).
Acute kidney injury
When including trials with low risk of bias, the administra-
tion of perioperative statins was associated with increased
incidence of postoperative AKI as compared with placebo
(314 of 1318 patients (23.82%) in the statin group versus
262 of 1319 patients (19.86%) in the placebo group; OR
1.26 (95% CI 1.05–1.52); p = 0.01; NNH 25) (Fig. 3). The
results are supported by the TSA, which showed firm evi-
dence for a 25% RRI (Additional file 1). The overall quality
of evidence was high according to GRADE.
The quantitative results of the systematic review are
displayed below and in Table 2 and supplementary ma-
terial (Additional file 1).
When including all the eligible trials despite the risk of
bias, statin therapy was associated with a non-significant
difference in AKI versus control (OR 1.18 (95% CI
0.99–1.41]; p = 0.06) (Fig. 3). Nonetheless, the latter
analysis was characterized by possible small-study publica-
tion bias and on sensitivity analyses the incidence of AKI
was higher with statin therapy (Additional file 1).
Atrial fibrillation
There was no difference in the rate of postoperative AF
in trials with low risk of bias (318 of 1268 (25.07%) in the
statin group and 300 of 1269 (23.64%) in the placebo
group, OR 1.08 (95% CI 0.90–1.30); p = 0.40) (Fig. 4) and
the TSA showed futility of the statin treatment when as-
suming an RRR of 20% (Additional file 1). The overall
quality of evidence was moderate.
On the contrary, the analysis that also included trials
with high and unclear risk of bias showed a lower inci-
dence of AF among patients allocated to statins (Fig. 4),
Fig. 1 Study flow diagram. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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Table 1 Characteristics of the trials included in the analysis
Trial Journal Cardiac surgery
procedure
Number of
patients
Statin Statin regimen Duration of
preoperative
therapy
Control Patients naïve to
statin therapy?
Outcomes for
meta-analysis
Risk of
bias
Almansob 2012 [31] Arterioscler Thromb
Vasc Biol
Non coronary cardiac
surgery
132 Simvastatin
20 mg
5–7 days preop and from
day 2 postop (no day 0)
5–7 days No
treatment
NR AF, MI, S, M High
Baran 2012 [32] Stem Vell Rev and
Rep
CABG 60 Atorvastatin
40 mg
2 weeks preop and postop
(no day 0)
2 weeks Placebo Yes (>3 months) AKI, AF, MI, S,
M
High
Berkan 2009 [33] Thorac Cardiov
Surg
CABG 46 Fluvastatin
80 mg
3 weeks preop 3 weeks Placebo Yes (>1 year) MI High
Billings 2016 [21] JAMA CABG (49%), valve, or
ascending aortic surgery
615 Atorvastatin
40 mg
Bid day 1b, qd day 0, and
qd postop
2 days Placebo No (Naïve 32%) AKI, AF, MI, S,
M, I
Low
Caorsi 2008 [34] Eur Cytokine Netw On-pump CABG 43 Pravastatin
40 mg
2 days preop, 1 hour after
CPB, and 7 days postop
2 days No
treatment
NR AF High
Carrascal 2016 [51] J Arrhythm Valve surgery 90 Atorvastatin
40 mg
7 days preop and 7 days
postop
7 days No
treatment
Yes AKI, AF, MI, S,
M
High
Castaño 2015 [35] J Cardiovasc Surg On-pump CABG 30 Pravastatin
80 or 40 mg
2 hours before surgery 1 days Placebo No (Naïve 0%) AF, MI, M Unclear
Chello 2006 [36] Crit Care Med On-pump CABG 40 Atorvastatin
20 mg
3 weeks preop 3 weeks Placebo Yes (>1 year) AKI, AF, MI, S,
M, I
Unclear
Christenson 1999
[37]
Eur J Cardiothorac
Surg
On-pump CABG 77 Simvastatin
20 mg
4 weeks preop 4 weeks No
treatment
NR AKI, MI, M, I High
Dehghani 2015 [38] J Cardiovasc
Pharmacol Ther
Valve surgery 58 Atorvastatin
40 mg
3 days preop and 5 days
postop
3 days Placebo Yes AF, MI, S, M Unclear
Ji 2009 [39] Circ J Off-pump CABG 140 Atorvastatin
20 mg
7 days preop 7 days Placebo Yes AF, MI, S, M High
Mannacio 2008 [40] J Thorac Cardiovasc
Surg
On-pump CABG 200 Rosuvastatin
20 mg
7 days preop 7 days Placebo Yes (>1 month) AKI, AF, MI, S,
M, I
High
Melina 2009 [41]a Eur Heart J On- off-pump CABG 632 Atorvastatin
40 mg
NR NR Placebo NR AF High
Park 2016 [42] Intensive Care
Med
Valve surgery 200 Atorvastatin
40 mg
Bid day 1, qd day 0, and
qd 3 days postopb
2 days Placebo Yes AKI, AF, MI, S,
M
Unclear
Patti 2006 [43] Circulation On-pump cardiac surgery
(CABG 79%)
200 Atorvastatin
40 mg
7 days preop and postop
until discharge (no day 0)
7 days Placebo Yes (>1 year) AF, MI, M High
Prowle 2012 [44] Nephrology On-pump cardiac surgery
(CABG 57%)
100 Atorvastatin
40 mg
Days 0 and 3 days postop 1 days Placebo No (Naïve 30%) AKI, M Low
Song 2008 [45] Am Heart J Off-pump CABG 124 Atorvastatin
20 mg
3 days preop, after surgery,
and 30 days postop
3 days No
treatment
Yes AF, MI, S High
Spadaccio 2010 [46] J Cardiovasc
Pharmacol
On-pump CABG 50 Atorvastatin
20 mg
3 weeks preop 3 weeks Placebo Yes (>1 year) AKI, AF, MI, S,
M, I
Unclear
Sun 2011 [47] Int Heart J On-pump CABG 100 Atorvastatin
20 mg
7 days preop 7 days Placebo Yes (>14 days) AF, MI High
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Table 1 Characteristics of the trials included in the analysis (Continued)
Tamayo 2009 [50] J Thorac Cardiovasc
Surg
On-pump CABG 44 Simvastatin
20 mg
3 weeks preop 3 weeks No
treatment
Yes (>3 weeks) AF, M High
Vukovic 2011 [48] Perfusion On-pump CABG 57 Atorvastatin
20 mg
3 weeks preop 3 weeks Placebo Yes (>1 year) AF, MI, M, I High
Youn 2011 [49] Korean J Thorac
Cardiovasc Surg
Off-pump CABG 142 Rosuvastatin
20 mg
Bid day 1, qd day 0 2 days No
treatment
No (Naïve 45%) MI, M High
Zheng 2016 [22] N Engl J Med On-pump CABG (42%),
off-pump CABG (43%),
AVR, AVR + CABG
1922 Rosuvastatin
20 mg
1–8 days preop and
5 days postop
8 days Placebo No (Naïve 66%) AKI, AF, MI,
S, M, I
Low
aAbstract-only publication. bPatients on chronic statin therapy received study drug only on day 0 and day 1, resuming chronic statin therapy on postoperative day 2. CABG coronary artery bypass grafting, AVR aortic
valve replacement, CPB cardiopulmonary bypass, preop preoperative regimen, postop postoperative regimen, day 0 the morning of the day of surgery, qd once a day, bid twice a day, AF atrial fibrillation, AKI acute
kidney injury, MI myocardial infarction, I infection, M mortality, NR not reported
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but TSA did not confirm the findings. There was signifi-
cantly high heterogeneity (p for heterogeneity = 0.0004, I2
60%) and important small-study publication bias; on sen-
sitivity analyses there was no difference in AF between
statins and control when including all eligible trials
despite their risk of bias (Additional file 1).
Myocardial infarction
The rate of postoperative MI did not change significantly
between groups among trials with low risk of bias (86 of
1268 (6.78%) in the statin group versus 88 of 1269
(6.93%) in the placebo group; OR 0.90 (95% CI 0.57–
1.42)) (Fig. 5) and TSA showed futility of the statin
treatment when assuming an RRR of 30% (Additional
file 1). The overall quality of evidence was moderate.
When including all trials regardless of the risk of bias,
statin therapy was not associated with a difference in post-
operative MI versus control (Fig. 5); publication bias was
present (Additional file 1).
Stroke
There was no difference in the rate of postoperative
stroke in trials with low risk of bias (15 of 1268 (1.18%)
in the statin group versus 12 of 1269 (0.95%) in the
placebo group; OR 1.25 (95% CI, 0.58–2.70)) and
TSA showed futility of the statin treatment when assum-
ing an RRR of 80%. The overall quality of evidence was
moderate. Including all trials, statin therapy was not
associated with a difference in the rate of postoperative
stroke (Additional file 1).
Infections
There was no difference in the rate of postoperative in-
fections between the statin and placebo groups in trials
with low risk of bias (88 of 1268 (6.94%) in the statin
group versus 108 of 1269 (8.51%) in the placebo group;
OR 0.80 (95% CI 0.60, 1.07)); on meta-analysis including
also trials with higher risk of bias there was no signifi-
cant difference between groups (Additional file 1). TSA
showed futility of the statin treatment only when includ-
ing all the eligible trials despite their risk of bias (Add-
itional file 1). The overall quality of evidence was low.
Mortality
The administration of perioperative statins was not asso-
ciated with a significant difference in hospital mortality
in trials with low risk of bias (9 of 1318 (0.68%) in the
statin group versus 2 of 1319 (0.15%) in the placebo
group; OR 1.26 [95% CI, 1.05-1.52]; p = 0.06) (Fig. 6);
TSA did not support this as firm evidence. The overall
quality of evidence was low. The sensitivity analysis
showed a small increase in hospital mortality in the sta-
tin group when changing the summary statistic (RD 0.01
(95%CI 0.00–0.01); p 0.04) (Additional file 1). There was
Fig. 2 Risk of bias summary: review authors' judgments about each
risk of bias item for each included study. Green circles indicate low
risk of bias, yellow circles indicate unclear risk of bias, and red circles
indicate high risk of bias
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no difference in short-term mortality when including
all eligible trials despite their risk of bias (Fig. 6).
Clinical outcomes and perioperative statin regimen
Meta-regression analysis of trials with low risk of bias
did not identify possible relationships between the length
of the preoperative regimen and clinical outcomes.
Meta-regression including all trials revealed a possible
relationship between the length of the preoperative regi-
men and AF, with patients on longer preoperative regi-
mens having a lower incidence of AF then patients on
shorter regimens (p = 0.024). However, the latter analysis
was driven mainly by the results of trials with unclear
and high risk of bias (Additional file 1).
Subgroup analysis including all trials addressing the ef-
fect of the presence or lack of a postoperative regimen
Table 2 Postoperative outcomes: effects of perioperative statin therapy versus control
Postoperative outcome Number of trials Number of patients OR (95% CI) P value Trial sequential analysis Level of evidence
Acute kidney injury
Trials with low risk of bias 3 2637 1.26 (1.05, 1.52) 0.01 Conclusive: harmful of statins High
All trials 10 3354 1.18 (0.99, 1.41)a 0.06 Inconclusive Low
Atrial fibrillation
Trials with low risk of bias 2 2537 1.08 (0.90, 1.30) 0.40 Conclusive: futility of statins Moderate
All trials 19 4737 0.80 (0.70, 0.91)a 0.001 Inconclusive Very low
Myocardial infarction
Trials with low risk of bias 2 2537 0.97 (0.71, 1.33) 0.87 Conclusive: futility of statins Moderate
All trials 18 4151 0.92 (0.69, 1.23)a 0.56 Conclusive: futility of statins Very low
Stroke
Trials with low risk of bias 2 2537 1.25 (0.58, 2.70) 0.56 Conclusive: futility of statins Low
All trials 11 3499 1.09 (0.60, 2.00) 0.77 Conclusive: futility of statins Very low
Infections
Trials with low risk of bias 2 2537 0.80 (0.60, 1.07) 0.14 Inconclusive Low
All trials 7 2724 0.78 (0.59, 1.04) 0.09 Conclusive: futility of statins Very low
Mortality
Trials with low risk of bias 3 2637 3.84 (0.95, 15.55) 0.06 Inconclusive Low
All trials 18 4157 1.92 (0.79, 4.66) 0.15 Inconclusive Very low
aEvidence of publication bias in favor of statins. Italics indicate statistical significance. OR odds ratio, CI confidence interval
Fig. 3 Postoperative acute kidney injury (AKI). Forest plot shows postoperative AKI in patients with perioperative statin therapy vs. control
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Fig. 4 Postoperative atrial fibrillation (AF). Forest plot shows postoperative AF in patients with perioperative statin therapy vs. control
Fig. 5 Postoperative myocardial infarction (MI). Forest plot shows postoperative MI in patients with perioperative statin therapy vs. control
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identified a significant subgroup difference for AKI
(chi-squared 4.68, p = 0.03) and AF (chi-squared 19.21,
p < 0.0001), suggesting a better outcome in patients not
taking postoperative statins. However, the analysis has
important limitations, as few trials did not administer
postoperative therapy and all these trials had high or
unclear risk of bias (Additional file 1).
Clinical outcomes in patients on chronic statin therapy or
statin-naïve patients
Among trials with low risk of bias, the only available
outcome to estimate was AF (2 trials, 2537 patients) with
no significant difference between statin-naïve patients or
those on chronic therapy (chi-squared 0.05, p = 0.82).
When including all the trials (19 trials, 4218 patients),
there were no significant differences between trials in-
cluding statin-naïve or mixed populations, except for
AF (chi-squared 5.69, p = 0.02). However, this analysis
should be interpreted with caution, because all the tri-
als enrolling only statin-naïve patients had high or un-
clear risk of bias (Additional file 1).
Clinical outcomes and CABG surgery
Meta-regression analysis did not reveal significant cor-
relation between the proportion of patients undergoing
CABG and the log-OR of any postoperative clinical out-
comes analyzed, even when including trials with higher
risk of bias (Additional file 1).
Effect of higher risk of bias, publication year, trial size,
and publication bias on clinical outcomes
Meta-regression including all trials demonstrated the in-
fluence of trial size (p = 0.02) and publication year (p <
0.01) on postoperative AF and AKI (Additional file 1).
This underlines that: (1) AKI and AF rates changed over
years, with results from older studies in favor of statins;
and (2) AKI and AF rates changed in relation to trial
sample size, with results from smaller trials in favor of
statins.
The presence of possible publication bias was suggested
when assessing the asymmetry of the funnel plot including
all the eligible trials; in particular, publication bias was evi-
dent in AKI, AF, and MI (see previous), suggesting that
small studies tended to report larger treatment effects in
favor of statin therapy than larger studies did.
Meta-analysis including trials with high and unclear risk
of bias (n = 20, 2465 patients) showed lower incidence of
AF in the statin group and no significant difference in
other postoperative outcomes (Additional file 1).
Discussion
This study determined the effect of perioperative statin
therapy on several postoperative outcomes in patients
undergoing cardiac surgery. Our primary analysis including
trials with low risk of bias showed that perioperative statin
therapy was associated with a significantly higher incidence
of AKI, whereas no other beneficial or detrimental effects
Fig. 6 Postoperative mortality. Forest plot shows postoperative short-term mortality in patients with perioperative statin therapy vs. control
(in-hospital or 30-day follow up)
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on AF, MI, stroke, and infections were highlighted; a
possible negative effect of statins on hospital mortality
could not be ruled out. Moreover, our systematic review
suggests that there is significant publication bias in favor
of statin therapy when including all trials, as small studies
and earlier studies, mostly with lower methodological
quality and higher risk of bias, appear to have overesti-
mated the beneficial effect of statins.
Statin administration is a cornerstone in lipid-lowering
therapy and in prevention of cardiovascular problems
[52], and after CABG surgery [53]. However, our system-
atic review highlights some important concerns involv-
ing the administration of this therapy in the days prior
to cardiac surgery, in such patients undergoing major
surgery at the risk of critical illness.
For many years, statin treatment was considered an at-
tractive therapy for reducing AKI following cardiac sur-
gery [54], an idea mainly based on retrospective data
[16, 55–59], and according to this hypothesis, some large
RCTs have been performed to test whether statins ef-
fectively decrease postoperative AKI [21, 42]. However,
RCTs support the lack of a kidney-protective effect
[21, 22, 42, 60, 61], as do the most recent systematic
reviews [17, 60]. The largest RCT performed so far showed
that rosuvastatin therapy resulted in a significantly higher
rate of AKI and higher plasma creatinine levels compared
to placebo at 48 hours after cardiac surgery [22]. Similarly,
the second largest RCT published by Billings et al. [21],
showed a non-significant trend in favor of placebo and a
possible detrimental effect of statin therapy in the small
subgroup of statin-naïve patients with chronic kidney dis-
ease. The authors suggested that the hypothetical associ-
ation between preoperative use of statins and decreased
postoperative AKI is inconsistent, suggesting that selection
bias for statin use, variable effects of treatment, and dispar-
ate patient populations could have affected the results of
prior retrospective trials attributing beneficial renal effects
to statins.
There is still much to be learnt about the mechanisms
of the possible negative effects of statin therapy on renal
function, and a class effect in patients undergoing cardiac
surgery cannot be ruled out. Mitochondrial dysfunction
related to statins is a well-known pathological event that
is frequently implicated in muscle adverse events; statins
could promote oxidation and apoptosis, and unmask si-
lent mitochondrial defects, leading to overall cellular en-
ergy imbalance [62]. It can be argued that mitochondrial
dysfunction can be deleterious even in organs other than
muscles, such as the kidneys, but no studies have explored
this. Other potential mechanisms may include myoglobin
nephropathy secondary to statin-induced rhabdomyolysis,
possibly aggravated by a higher statin blood level due to
drug interactions [62], and insulin resistance/aggravation
of diabetes [62, 63].
According to high-quality evidence, there is no signifi-
cant difference in the postoperative incidence of AF. On
the other hand, we found conflicting results when includ-
ing trials with higher risk of bias, but this analysis was
characterized by significant small-study publication bias
and significantly high heterogeneity. The results of larger
RCTs [21, 22] conflict with those of several smaller RCTs
[36, 39, 40, 43, 50, 64, 65], as smaller studies suggested
that perioperative statin therapy, as compared with con-
trol, halved the incidence of postoperative AF. The assess-
ment of postoperative AF could be biased due to several
factors; for instance, continuous electrocardiogram
monitoring during the study, definition of postoperative
AF, and blinding of the personnel. In the largest RCT
performed so far with postoperative AF as the primary
endpoint, the incidence of postoperative AF did not dif-
fer significantly between patients receiving Rosuvastatin
and those receiving placebo [22].
There was no significant difference in postoperative
MI in association with perioperative statins. In the
largest RCTs performed so far there was no difference in
postoperative MI [21, 22] and myocardial injury, defined
as difference in postoperative creatinine kinase-myocardial
band (CK-MB) [21] and troponin I [22] release. In
addition, we found no difference in postoperative stroke,
another crucial cardiovascular complication associated to
severe morbidity.
Statins have been thought to decrease postoperative
infection [66], but our analysis ruled out a possible role
in this field, as was also shown in other trials in a critical
care setting, in which statin therapy had no effects on
the progression of infection and mortality [67, 68].
According to randomized evidence, perioperative statins
do not decrease short-term mortality, although an increase
in hospital mortality among our population with low risk
of bias could not be excluded. Future RCTs should explore
this field, with particular attention to long-term mortality.
Interestingly, the results of our systematic review are not in
accordance with findings of previous observational studies
[69] and meta-analyses including non-randomized studies
and small randomized studies [16, 17], in which the
authors describe a clear short-term mortality benefit
mediated by perioperative statins compared to control;
however, the retrospective design and the high risk of
bias of the trials included make these results inconsistent.
With a total of 23 randomized trials and a cumulative pa-
tient cohort of 5102 patients, this was the largest meta-
analysis of RCTs performed so far. The largest previous
meta-analysis of RCTs included only 17 trials and 2138 pa-
tients and found no difference in any postoperative out-
comes except for AF. However, the results of the
aforementioned review were mainly driven by data with
high risk of bias and did not include the two largest re-
cently performed trials with low risk of bias trials [21, 22].
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The included trials with low risk of bias were placebo-
controlled, recruiting 2637 patients, 43% already on statin
therapy, who underwent CABG surgery in about 78% of
the cases. Current guidelines suggest that all patients
undergoing CABG should receive or continue statin ther-
apy, unless it is contraindicated, and statin discontinuation
is not recommended before or after CABG because of
possible harmful effects. In light of the results of the
present systematic review and of the recently published
high-quality trials [21, 22], the class and level of evidence
of these recommendations should be revised, as current
randomized evidence does not support the broad use of
statin therapy in the perioperative period to improve
patients’ outcomes. However, even if the majority of
patients included in our analysis underwent CABG, we
cannot rule out a possible class effect of statin therapy,
although our meta-regression and the larger published
trials [21, 22] did not suggest subpopulation effects.
In the authors’ opinion, this meta-analysis would sup-
port a neutral effect of perioperative statin therapy or
perhaps weak evidence of a clinically significant detrimen-
tal effect on patients’ outcomes. The exact time-point for
interruption of preoperative statin therapy in patients
already taking a statin should be further evaluated. Billings
and colleagues randomized patients on chronic statin
therapy to intervention only on the day of the surgery and
on the first postoperative day [21]. On the other hand,
Zheng and colleagues interrupted statin therapy during
the 8 days before surgery, with about two thirds of the pa-
tients having therapy interrupted during the 4 days before
surgery [22]. However, the length of perioperative statin
regimen varies among trials and no recommendations
could be made.
Strengths and limitations
One of the preferable meta-analytical strategies is to re-
strict the primary analysis to studies at low risk of bias
[23, 26]. The choice should be based on the balance be-
tween the potential for bias and the loss of precision
when studies at high and unclear risk of bias are excluded
[26]. Among the randomized literature, we found signifi-
cant small-study publication bias and serious differences
in risk of bias within studies. We must recognize that
publication bias is common in peer-reviewed journals
and particularly in critical care medicine [70], because
positive studies are easier and more attractive to publish
than neutral or negative studies [71], and small trials
are more likely to report larger beneficial effects than
large trials, which could be partly explained by the
lower methodological quality in smaller trials [70]. It is
noteworthy that the largest trials with low risk of bias
performed so far on the topic had neutral or negative re-
sults from analysis of the use of perioperative statins in
cardiac surgery patients [21, 22]. To this end, we think
that our per-protocol primary analysis, including only ran-
domized placebo-controlled trials with low risk of bias,
could have limited this problem. However, only three trials
with low risk of bias with a total of 2637 patients have
been published so far and included in our primary analysis.
There is some degree of variability in the nature of
statin therapy, because statins may be administered
using different strategies, some of which may be more ef-
fective than others; for example, there is non-randomized
evidence to support an increased rate of AKI among pa-
tients taking high-potency statins, with the strongest rate in
the first 4 months after initiation of treatment [72]. We did
not perform subgroup analysis of different types of peri-
operative statin regimens, because almost all the trials ad-
ministered different statin doses and formulations for
different lengths of time, and the analysis would have been
biased by results of trials with higher risk of bias. Finally,
our mortality analysis included short-term mortality (in-
hospital and 30-day mortality), addressing the fact that
mortality should be assessed after longer follow up, in order
to evidence the long-term effects of the interventions.
Future directions
This systematic review synthesized evidence from RCTs
and may help the execution of future clinical studies
assessing the exact time point for interruption of preopera-
tive statin therapy in patients already taking statins. Further
RCTs should systematically evaluate the relationship be-
tween postoperative outcomes and variables related to the
patient (e.g., chronic kidney disease, statin-naïvety), to the
cardiac disease (e.g., coronary artery disease), to the surgi-
cal procedure (e.g., off-pump versus on-pump surgery),
and to the specific statin regimen.
Conclusions
Our results suggest that perioperative statin therapy is
not protective against postoperative AF, MI, stroke, or
infection. Instead, statins might be associated with higher
postoperative AKI and a possible negative effect on short-
term survival could not be excluded. Open questions on
patient population, preexisting chronic disease, and length
and dose of the treatment need to be clarified by further
high-quality RCTs, assessing the more appropriate time
point for discontinuation of statins before cardiac surgery.
Additional files
Additional file 1: Supplementary material. (PDF 2.18 mb)
Abbreviations
AF: atrial fibrillation; AKI: acute kidney injury; CABG: coronary artery bypass
grafting; CI: confidence interval; MI: myocardial infarction; NNH: number
needed to harm; NNT: number needed to treat; OR: odds ratio;
Putzu et al. Critical Care  (2016) 20:395 Page 12 of 14
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses;
RCT: randomized controlled trial; RRI: relative risk increase; RRR: relative risk
reduction; TSA: trials sequential analysis
Acknowledgements
Not applicable
Funding
The study and the authors did not receive any financial support.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its supplementary information files.
Authors’ contributions
Study design: AP, GL, TC; study conduct: AP, GL, AB, BC; data analysis: AP, AB,
GL; data interpretation: AP, BC, AB, TC, EF, MG, GC, GL; writing and revising
paper: AP, BC, AB, TC, EF, MG, GC, GL. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1 Department of Cardiovascular Anesthesia and Intensive Care, Cardiocentro
Ticino, Via Tesserete 48, Lugano, Switzerland. 2Department of Anesthesia and
Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milano,
Italy. 3Department of Cardiac Surgery, Cardiocentro Ticino, Via Tesserete 48,
Lugano, Switzerland. 4Vita-Salute San Raffaele University, Via Olgettina 58,
Milano, Italy.
Received: 30 August 2016 Accepted: 7 November 2016
References
1. LaPar DJ, Crosby IK, Rich JB, Fonner E, Kron IL, Ailawadi G, et al. A
contemporary cost analysis of postoperative morbidity after coronary artery
bypass grafting with and without concomitant aortic valve replacement
to improve patient quality and cost-effective care. Ann Thorac Surg.
2013;96:1621–7.
2. Kim LK, Looser P, Swaminathan RV, Minutello RM, Wong SC, Girardi L, et al.
Outcomes in patients undergoing coronary artery bypass graft surgery in
the United States based on hospital volume, 2007 to 2011. J Thorac
Cardiovasc Surg. 2016;151:1686–92.
3. Beckmann A, Funkat A-K, Lewandowski J, Frie M, Ernst M, Hekmat K, et al.
Cardiac surgery in Germany during 2014: a report on behalf of the German
Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg.
2015;63:258–69.
4. Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, et
al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors.
Circulation. 2009;119:495–502.
5. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery.
Clin J Am Soc Nephrol. 2006;1:19–32.
6. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et
al. Rate control versus rhythm control for atrial fibrillation after cardiac
surgery. N Engl J Med. 2016;374:1911–21.
7. Helgadottir S, Sigurdsson MI, Ingvarsdottir IL, Arnar DO, Gudbjartsson T,
Almassi G, et al. Atrial fibrillation following cardiac surgery: risk analysis and
long-term survival. J Cardiothorac Surg. 2012;7:87.
8. Svircevic V, Nierich AP, Moons KGM, Brandon Bravo Bruinsma GJ, Kalkman
CJ, van Dijk D. Fast-track anesthesia and cardiac surgery: a retrospective
cohort study of 7989 patients. Anesth Analg. 2009;108:727–33.
9. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011
ACCF/AHA guideline for coronary artery bypass graft surgery: executive
summary: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. J Thorac
Cardiovasc Surg. 2012;143:4–34.
10. Kulik A, Levin R, Ruel M, Mesana TG, Solomon DH, Choudhry NK. Patterns
and predictors of statin use after coronary artery bypass graft surgery.
J Thorac Cardiovasc Surg. 2007;134:932–8.
11. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-
methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease:
a comprehensive review. Cardiol Rev. 18:298–304.
12. Sodha NR, Sellke FW. The effect of statins on perioperative inflammation in
cardiac and thoracic surgery. J Thorac Cardiovasc Surg. 2015;149:1495–501.
13. Dotani MI, Morise AP, Haque R, Jain AC, Gupta N, Gibson CM. Association
between short-term simvastatin therapy before coronary artery bypass
grafting and postoperative myocardial blood flow as assessed by positron
emission tomography. Am J Cardiol. 2003;91:1107–9.
14. Pan W, Pintar T, Anton J, Lee V-V, Vaughn WK, Collard CD. Statins are
associated with a reduced incidence of perioperative mortality after
coronary artery bypass graft surgery. Circulation. 2004;110:II45–9.
15. Pascual DA, Arribas JM, Tornel PL, Marín F, Oliver C, Ahumada M, et al.
Preoperative statin therapy and troponin T predict early complications of
coronary artery surgery. Ann Thorac Surg. 2006;81:78–83.
16. Liakopoulos OJ, Choi Y-H, Haldenwang PL, Strauch J, Wittwer T, Dörge H, et
al. Impact of preoperative statin therapy on adverse postoperative
outcomes in patients undergoing cardiac surgery: a meta-analysis of over
30,000 patients. Eur Heart J. 2008;29:1548–59.
17. Kuhn EW, Liakopoulos OJ, Stange S, Deppe A-C, Slottosch I, Choi Y-H, et al.
Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000
patients. Eur J Cardiothorac Surg. 2014;45:17–26. discussion 26.
18. Marín F, Pascual DA, Roldán V, Arribas JM, Ahumada M, Tornel PL, et al.
Statins and postoperative risk of atrial fibrillation following coronary artery
bypass grafting. Am J Cardiol. 2006;97:55–60.
19. Tabata M, Khalpey Z, Pirundini PA, Byrne ML, Cohn LH, Rawn JD.
Renoprotective effect of preoperative statins in coronary artery bypass
grafting. Am J Cardiol. 2007;100:442–4.
20. Coleman CI, Lucek DM, Hammond J, White CM. Preoperative statins and
infectious complications following cardiac surgery. Curr Med Res Opin.
2007;23:1783–90.
21. Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG,
et al. High-dose perioperative Atorvastatin and acute kidney injury
following cardiac surgery: a randomized clinical trial. JAMA.
2016;315:877–88.
22. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, et al. Perioperative
Rosuvastatin in cardiac surgery. N Engl J Med. 2016;374:1744–53.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration, 2011. Available from www.handbook.cochrane.org.
24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al.
The PRISMA statement for reporting systematic reviews and meta-analyses
of studies that evaluate healthcare interventions: explanation and elaboration.
BMJ. 2009;339:b2700.
25. Landoni G, Putzu A, Capelli B, Belletti A. Perioperative statin therapy in
cardiac surgery: a meta-analysis of randomized controlled trials [Internet].
Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42016039509. Accessed 23 Nov 2016.
26. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.
The Cochrane Collaboration’s tool for assessing risk of bias in randomised
trials. BMJ. 2011;343:d5928.
27. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.
GRADE: an emerging consensus on rating quality of evidence and strength
of recommendations. BMJ. 2008;336:924–6.
28. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may
establish when firm evidence is reached in cumulative meta-analysis. J Clin
Epidemiol. 2008;61:64–75.
29. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals
insufficient information size and potentially false positive results in many
meta-analyses. J Clin Epidemiol. 2008;61:763–9.
30. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JPA, Thabane L,
et al. Can trial sequential monitoring boundaries reduce spurious inferences
from meta-analyses? Int J Epidemiol. 2009;38:276–86.
31. Almansob MAS, Xu B, Zhou L, Hu X-X, Chen W, Chang F-J, et al. Simvastatin
reduces myocardial injury undergoing noncoronary artery cardiac surgery: a
randomized controlled trial. Arterioscler Thromb Vasc Biol. 2012;32:2304–13.
Putzu et al. Critical Care  (2016) 20:395 Page 13 of 14
32. Baran Ç, Durdu S, Dalva K, Zaim Ç, Dogan A, Ocakoglu G, et al. Effects of
preoperative short term use of atorvastatin on endothelial progenitor cells after
coronary surgery: a randomized, controlled trial. Stem Cell Rev. 2012;8:963–71.
33. Berkan O, Katrancioglu N, Ozker E, Ozerdem G, Bakici Z, Yilmaz MB. Reduced
P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients
undergoing open heart surgery. Thorac Cardiovasc Surg. 2009;57:91–5.
34. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and C-
reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass.
Eur Cytokine Netw. 2008;19:99–103.
35. Castaño M, González-Santos JM, López J, García B, Centeno JE, Aparicio B, et al.
Effect of preoperative oral pravastatin reload in systemic inflammatory response
and myocardial damage after coronary artery bypass grafting. A pilot double-
blind placebo-controlled study. J Cardiovasc Surg (Torino). 2015;56:617–29.
36. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, et al.
Effects of atorvastatin on systemic inflammatory response after coronary
bypass surgery. Crit Care Med. 2006;34:660–7.
37. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk
of postoperative thrombocytosis and thrombotic complications following
CABG. Eur J Cardiothorac Surg. 1999;15:394–9. 400.
38. Dehghani MR, Kasianzadeh M, Rezaei Y, Sepehrvand N. Atorvastatin reduces
the incidence of postoperative atrial fibrillation in statin-naive patients
undergoing isolated heart valve surgery: a double-blind, placebo-controlled
randomized trial. J Cardiovasc Pharmacol Ther. 2015;20:465–72.
39. Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, et al. Effect of preoperative
atorvastatin therapy on atrial fibrillation following off-pump coronary artery
bypass grafting. Circ J. 2009;73:2244–9.
40. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of
rosuvastatin pretreatment on myocardial damage after coronary surgery: a
randomized trial. J Thorac Cardiovasc Surg. 2008;136:1541–8.
41. Melina G, Angeloni E, Di Nucci G, Benedetto U, Fiorani B, Sclafani G, et al.
Preoperative HMG-CoA reductase inhibitors and atrial fibrillation in patients
undergoing CABG: a prospective randomised trial. Eur Hear J. 2009;30:32.
42. Park JH, Shim J-K, Song J-W, Soh S, Kwak Y-L. Effect of atorvastatin on the
incidence of acute kidney injury following valvular heart surgery: a
randomized, placebo-controlled trial. Intensive Care Med. 2016;42:1398–407.
43. Patti G, Chello M, Candura D, Pasceri V, D’Ambrosio A, Covino E, et al.
Randomized trial of atorvastatin for reduction of postoperative atrial
fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3
(Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery)
study. Circulation. 2006;114:1455–61.
44. Prowle JR, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Haase M, et al. Pilot
double-blind, randomized controlled trial of short-term atorvastatin for
prevention of acute kidney injury after cardiac surgery. Nephrology
(Carlton). 2012;17:215–24.
45. Bin SY, On YK, Kim JH, Shin D-H, Kim JS, Sung J, et al. The effects of atorvastatin
on the occurrence of postoperative atrial fibrillation after off-pump coronary
artery bypass grafting surgery. Am Heart J. 2008;156:373. e9-16.
46. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, et al.
Atorvastatin increases the number of endothelial progenitor cells after cardiac
surgery: a randomized control study. J Cardiovasc Pharmacol. 2010;55:30–8.
47. Sun Y, Ji Q, Mei Y, Wang X, Feng J, Cai J, et al. Role of preoperative
atorvastatin administration in protection against postoperative atrial
fibrillation following conventional coronary artery bypass grafting.
Int Heart J. 2011;52:7–11.
48. Vukovic PM, Maravic-Stojkovic VR, Peric MS, Jovic MD, Cirkovic MV, Gradinac SD,
et al. Steroids and statins: an old and a new anti-inflammatory strategy
compared. Perfusion. 2011;26:31–7.
49. Youn Y-N, Park S-Y, Hwang Y, Joo H-C, Yoo K-J. Impact of high-dose statin
pretreatment in patients with stable angina during off-pump coronary
artery bypass. Korean J Thorac Cardiovasc Surg. 2011;44:208–14.
50. Tamayo E, Alvarez FJ, Alonso O, Bustamante R, Castrodeza J, Soria S, et al.
Effects of simvastatin on systemic inflammatory responses after
cardiopulmonary bypass. J Cardiovasc Surg (Torino). 2009;50:687–94.
51. Carrascal Y, Arnold RJ, De la Fuente L, Revilla A, Sevilla T, Arce N, et al.
Efficacy of atorvastatin in prevention of atrial fibrillation after heart valve
surgery in the PROFACE trial (PROphylaxis of postoperative atrial Fibrillation
After Cardiac surgEry). J Arrhythm Elsevier. 2016;32:191–7.
52. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al.
Interpretation of the evidence for the efficacy and safety of statin therapy.
Lancet. 2016;0:2152–61.
53. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, et al.
Secondary prevention after coronary artery bypass graft surgery. Circulation.
2015;131:927-964.
54. Bellomo R. Perioperative statins in cardiac surgery and acute kidney injury.
JAMA. 2016;315:873–4.
55. Layton JB, Hansen MK, Jakobsen C-J, Kshirsagar AV, Andreasen JJ, Hjortdal VE,
et al. Statin initiation and acute kidney injury following elective cardiovascular
surgery: a population cohort study in Denmark†. Eur J Cardiothorac Surg.
2016;49:995–1000.
56. Layton JB, Kshirsagar AV, Simpson RJ, Pate V, Jonsson Funk M, Stürmer T, et
al. Effect of statin use on acute kidney injury risk following coronary artery
bypass grafting. Am J Cardiol. 2013;111:823–8.
57. Molnar AO, Parikh CR, Coca SG, Thiessen-Philbrook H, Koyner JL, Shlipak MG,
et al. Association between preoperative statin use and acute kidney injury
biomarkers in cardiac surgical procedures. Ann Thorac Surg. 2014;97:2081–7.
58. Wang J, Gu C, Gao M, Yu W, Yu Y. Preoperative statin therapy and renal
outcomes after cardiac surgery: a meta-analysis and meta-regression of
59,771 patients. Can J Cardiol. 2015;31:1051–60.
59. Brunelli SM, Waikar SS, Bateman BT, Chang TI, Lii J, Garg AX, et al.
Preoperative statin use and postoperative acute kidney injury. Am J Med.
2012;125:1195–204. e3.
60. Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy
for patients undergoing cardiac surgery. Cochrane Database Syst Rev.
2015;13:CD008493.
61. Lewicki M, Ng I, Schneider AG. HMG CoA reductase inhibitors (statins) for
preventing acute kidney injury after surgical procedures requiring cardiac
bypass. Cochrane Database Syst Rev. 2015;11:CD010480.
62. Golomb BA, Evans MA. Statin adverse effects : a review of the literature and
evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs.
2008;8:373–418.
63. Kain V, Kapadia B, Misra P, Saxena U, Mol MJ, Erkelens DW, et al. Simvastatin
may induce insulin resistance through a novel fatty acid mediated cholesterol
independent mechanism. Sci Rep. 2015;5:13823.
64. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang M-H, Paschalis A,
et al. Preoperative atorvastatin treatment in CABG patients rapidly improves
vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity.
Circulation. 2010;122:S66–73.
65. Rezaei Y, Gholami-Fesharaki M, Dehghani MR, Arya A, Haghjoo M, Arjmand N.
Statin antiarrhythmic effect on atrial fibrillation in statin-naive patients
undergoing cardiac surgery: a meta-analysis of randomized controlled
trials. J Cardiovasc Pharmacol Ther. 2016;21:167–76.
66. Trezzi M, Blackstone EH, Sun Z, Li L, Sabik JF, Lytle BW, et al. Statin therapy
is associated with fewer infections after cardiac operations. Ann Thorac
Surg. 2013;95:892–900.
67. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network,
Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, et al. Rosuvastatin
for sepsis-associated acute respiratory distress syndrome. N Engl J Med.
2014;370:2191–200.
68. Papazian L, Roch A, Charles P-E, Penot-Ragon C, Perrin G, Roulier P, et al.
Effect of statin therapy on mortality in patients with ventilator-associated
pneumonia: a randomized clinical trial. JAMA. 2013;310:1692–700.
69. Clark LL, Ikonomidis JS, Crawford FA, Crumbley A, Kratz JM, Stroud MR, et al.
Preoperative statin treatment is associated with reduced postoperative
mortality and morbidity in patients undergoing cardiac surgery: an 8-year
retrospective cohort study. J Thorac Cardiovasc Surg. 2006;131:679–85.
70. Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical
care meta-analyses: a meta-epidemiological study. Crit Care. 2013;17:R2.
71. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in
clinical trials due to statistical significance or direction of trial results.
Cochrane Database Syst Rev. 2009;(1):MR000006.
72. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB,
et al. Use of high potency statins and rates of admission for acute kidney
injury: multicenter, retrospective observational analysis of administrative
databases. BMJ. 2013;346:f880.
Putzu et al. Critical Care  (2016) 20:395 Page 14 of 14
